[ad_1] Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock popped more than 47%…
Tag: Karuna Therapeutics Inc
Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia
[ad_1] With new drug launches and product approvals on the horizon, some biotechnology stocks could finally be due for a breakout, market participants say. Biotech investors could use a break.…